Hinge Health price target raised to $55 from $50 at RBC Capital

RBC Capital analyst Rishi Jaluria raised the firm’s price target on Hinge Health (HNGE) to $55 from $50 and keeps an Outperform rating on the shares after hosting investor meetings with the company. Hinge management believes that HingeSelect can be a meaningful additional revenue stream as providers are incentivized to take part in HingeSelect as it offers payment certainty and pipeline generation, the analyst tells investors in a research note. RBC further cites the magement continuing to invest in total addressable market expansion opportunities, as the company has already expanded to adjacent areas like women’s pelvic health, menopause, and fall prevention.